| Comment
|
taken from DrugBank
|
| Curator
|
Ab +
|
| DefiningCitation
|
http://www.drugbank.ca/drugs/DB00106 +
|
| Definition
|
Synthetic decapeptide antagonist to gonado … Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. Pharmacology: Used in the palliative treatment of advanced prostate cancer. Abarelix is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis. Mechanism of action: Abarelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion. Drug type: Approved. Biotech. Investigational. Withdrawn. Drug category: Anti-Testosterone Agents. Antineoplastic Agents Testosterone Agents. Antineoplastic Agents
|
| Has role
|
Drug +
|
| Id
|
DB00106 +
|
| Label
|
Abarelix +
|
| Modification dateThis property is a special property in this wiki.
|
5 February 2010 03:22:13 +
|
| ModifiedDate
|
5 February 2010 +
|
| RelatedTo
|
Gonadotrophin-releasing hormone +
|
| SuperCategory
|
Molecule +
|
| Synonym
|
abarelix +,
Plenaxis +,
Plenaxis (Praecis Pharmaceuticals) +
|
| Categories |
Molecule
|
